Day One Biopharma Q2 Earnings: OJEMDA Revenue Soars 310%, Cash Position at $453M

Day One Biopharmaceuticals reported Q2 2025 net product revenue of $33.6mln, a 10% increase from the previous quarter and a 310% rise YoY. The company ended the quarter with a strong cash position of $453.1mln. OJEMDA prescriptions exceeded 1,000, and full-year revenue is expected to be between $140 and $150mln. The company is progressing with its clinical trials, including the Phase 3 FIREFLY-2 trial. Despite a net loss of $30.3mln, Day One reduced its R&D expenses significantly compared to the previous year.

Day One Biopharmaceuticals Inc. (DAWN) reported robust financial results for the second quarter of 2025, with net product revenue of $33.6 million, marking a 10% increase from the previous quarter and a 310% year-over-year rise. The company's strong commercial momentum was further underscored by the issuance of full-year net product revenue guidance, projecting total net revenues of between $140 million and $150 million for 2025 [1].

The company's Q2 2025 net product revenue of $33.6 million represents a significant milestone, with total prescriptions for Ogenda exceeding 1,000 for the first time. This strong performance was driven by double-digit top-line revenue growth in the quarter, with the company reporting a 10% increase over Q1 2025 [1]. The positive reception of the two-year data on Ogenda's efficacy has led to an uptick in new patient starts, contributing to the quarter's growth [2].

Day One Biopharmaceuticals maintains a strong financial position, ending the quarter with $453.1 million in cash and no debt. This substantial cash position provides the company with flexibility to execute strategic plans and continue its clinical trial programs [1].

The company's continued investment in Ogenda's development is evident in its progress with the Phase 3 FIREFLY-2 trial. Additionally, Day One has discontinued its investment in the VRK1 program to focus on advancing the PTK7-targeted ADC, DAY301, through Phase Ia dose escalation [2].

Despite the strong performance, Day One faces challenges in ensuring persistence on therapy and the pace of new patient starts to meet revenue guidance. The company is investing in physician education to manage adverse events and reduce dropouts, with a focus on establishing Ogenda as a standard of care [2].

The company's Q&A session highlighted the two key variables critical to defining the range for revenue guidance: continued adoption in the form of new patient starts and persistence on therapy [1]. Management expressed confidence in these growth drivers, projecting strong and persistent demand for Ogenda in the coming quarters.

References:
[1] https://finance.yahoo.com/news/day-one-biopharmaceuticals-inc-dawn-073133959.html
[2] https://seekingalpha.com/news/4479398-day-one-biopharmaceuticals-outlines-140m-150m-2025-ojemda-revenue-target-as-new-patient